Part, Chapter, Paragraph
501 III, 10. 6. 3 | shows national rates.~ ~Figure 10.6.3.1. Prevalence rates
502 IV, 11. 1. 5 | Hungary (less than 3.5) (See Figure 11.1). In most countries,
503 IV, 11. 1. 5 | healthcare system as a whole.~ ~Figure 11.1. Overall satisfaction
504 IV, 11. 2. 1 | across the European region (Figure 11.2). When examining the
505 IV, 11. 2. 1 | funded largely by taxation.~ ~Figure 11.2.Number of hospital
506 IV, 11. 3. 2 | markets in China and India.~ ~Figure 11.4. Relative prices of
507 IV, 11. 3. 2 | into priority diseases.~ ~Figure 11.5. Current levels of
508 IV, 11. 3. 2 | anti-neoplastic agents (figure 11.5).~ ~Therapeutic focus
509 IV, 11. 3. 2 | for the years 2008-2010~ ~Figure 11.6. Therapeutic focus
510 IV, 11. 3. 2 | the overall product-mix (figure 11.6.).~ ~
511 IV, 11. 4 | research and decision-making. Figure 11.7 depicts how HTA projects
512 IV, 11. 4 | inform specific policies.~ ~Figure 11.7. Relations between
513 IV, 11. 4 | cannot all be covered by HTA (Figure 11.8).~ ~Figure 11.8. HTA
514 IV, 11. 4 | by HTA (Figure 11.8).~ ~Figure 11.8. HTA as an input to
515 IV, 11. 4 | described as depicted in Figure 11.9. The key point that
516 IV, 11. 4 | epidemiologic studies etc.~ ~Figure 11.9. Conduction of an assessment~ ~ ~
517 IV, 11. 5. 1 | donation is extremely varied (Figure 11.10):~· a few nations
518 IV, 11. 5. 1 | tissue transplantation.~ ~Figure 11.10. International Figures
519 IV, 11. 5. 3 | organ transplantation (figure 11.12) organ exchange and
520 IV, 11. 5. 3 | Figures from 11.11 to 11.14.~ ~Figure 11.11. Organ Procurement
521 IV, 11. 5. 3 | different European countries~Figure 11.12. Organ transplantation
522 IV, 11. 5. 3 | different European countries~Figure 11.13. Exchanges and import/
523 IV, 11. 5. 3 | different European countries~Figure 11.14. Percentage and absolute
524 IV, 11. 5. 3 | have technical guidelines.~Figure 11.15 shows the different
525 IV, 11. 5. 3 | guidelines or not regulated).~ ~Figure 11.15. Risk assessment criteria
526 IV, 11. 5. 3 | in technical guidelines. Figure 11.16 shows the biological
527 IV, 11. 5. 3 | donor characteristics.~ ~Figure 11.16. Biological tests
528 IV, 11. 5. 3 | in organ transplant~ ~As Figure 11.16 shows, there is consensus
529 IV, 11. 5. 3 | out for donor evaluation, Figure 11.17 shows the different
530 IV, 11. 5. 3 | tests on a routine basis.~ ~Figure 11.17. Tumour markers in
531 IV, 11. 5. 3 | transplants number of countries~ ~Figure 11.18 shows the different
532 IV, 11. 5. 3 | technical guidelines:~ ~Figure 11.18. Organ transplantation
533 IV, 11. 5. 4 | European countries (see Figure 11.10). These differences
534 IV, 11. 6. 2 | Cyprus, Greece and Latvia (Figure 11.19). Unfortunately, available
535 IV, 11. 6. 2 | Norway~- Poland~ ~ ~ ~Figure 11.19. Out-of-pocket payments (
536 IV, 12. 5 | and Jagger, in press).~ ~Figure 12.A1.1a Trend in the proportion
537 IV, 12. 5 | EU Member States - men.~ ~Figure 12.A1.1b Trend in the proportion
538 IV, 13. 2. 2 | cancer) dominate the picture (Figure 13.1).~ ~Figure 13.1. Patterns
539 IV, 13. 2. 2 | picture (Figure 13.1).~ ~Figure 13.1. Patterns of total
540 IV, 13. 2. 2 | life years) lost. A similar figure was found for the World
